Chart of the Day: Halozyme Therapeutics (HALO)
Keep an eye on Halozyme Therapeutics (HALO). Last trading at $60.81, we’d like to see it refill its bearish gap at around $64 initially. Helping, analysts at Morgan Stanley just upgraded HALO to overweight with a price target of $75. The firm believes the...
						









